Vindesine in the Treatment of Leukaemia

References

• Dancey J., Steward W. P. The role of vindesine in oncology—recommendations after 10 years' experience. Anti-Cancer Drugs 1995; 6: 625–636
   PubMed Web of Science ®Google Scholar
• Cersosimo R. J., Bromer R., Licciardello J. T. W., Hong W. K. Pharmacology, clinical efficacy and adverse effects of vindesine sulfate, a new vinca alkaloid. Pharmacotherapy 1983; 3: 259–274
   PubMed Web of Science ®Google Scholar
• Zhou X. J., Placidi M., Steward W. P. Uptake and metabolism of vinca alkaloids by freshly isolated human hepatocytes in suspension. Anti-Cancer Res. 1994; 14: 1017–1022
   PubMed Web of Science ®Google Scholar
• Brade W. P. Critical review of pharmacology, toxicology, phannacokinetics of vincristine, vindesine, vinblas-tine. Proceedings of the International Vinca Alkaloid Symposium—. Vindesine 1980; 6: 95
   Google Scholar
• Mathe G., Hulhoven R., Sokal G., Bayssas M., Belpomme D., Bosly A., Cornu G., Delannoy A., De Luca L., De Vassal F., Ferrant A., Gouveia J., Hayat M., Jasmin C., Machover D., Michaux J. L., Misset J. L., Musset M., Pico J. L., Ribaud P., Schwartzenberg L. Phase II clinical trials with vindesine in patients with haematologic malignancies. Anti-Cancer Research 1981; 1: 1–9
   Web of Science ®Google Scholar
• Schrappe M., Reiter A., Sauter S., Ludwig W. D., WÖRman B., Harbott J., Bender-GÖTze C., DÖRffel W., Dopfer R., Frey E., Havers W., Henze G., KÜHl J., Richter R., Ritter J., Treuner J., Zintl F., Odenwald E., Welte K., Riehm H. Konzeption und Zwischenergebnis der Therapiestudie ALL-BFM 90 zur Behandlung der akuten lym-phoblastischen Leukkämie bei Kindem unde Jugendlichen: Die Bedeutung des initialen Therapieansprechens in Blut un Knochenmark. Klin. Pädiatr. 1994; 206: 208–221
   PubMed Web of Science ®Google Scholar
• Bayssas M., Gouveia J., De Vassal F., Misset J. L., Schwarzenberg L., Ribaud P., Musset M., Jasmin C., Hayat M., Mathe G. Vindesine: a new vinca alkaloid. Recent Results Cancer Res. 1980; 74: 91–97
   PubMedGoogle Scholar
• Ettinger L. J., Brecher M., Coleman M., Smithson W. A., Patterson R., Russell E. C., Necheles; T., Jones B., Ohnuma T. Vindesine: a phase II study in childhood malignancies—a report for cancer and leukemia group B. Med. Pediatr. Oncol. 1982; 10: 35–43
   PubMedGoogle Scholar
• Mandelli F., Amadori S., Giona F., Antonietta M., Spiriti A., Pastore S., Meloni G., Paolucci G. Vindesine in the treatment of refractory haematologic malignancies: a phase II study. Leuk. Res. 1982; 6: 649–652
   PubMed Web of Science ®Google Scholar
• Hulhoven R., Michaux J. L., Cornu G., Ferrant A., Bosly A., Delannoy A., Sokal G. A phase II study of vindesine in patients with hematological malignancies. Biomedicine 1980; 33: 31–32
   PubMedGoogle Scholar
• Dyke R. W., Nelson R. L., Brade W. P. Vindesine. a short review of preclinical and first clinical data. Cancer Chemother. Pharmacol. 1979; 2: 229–232
   PubMed Web of Science ®Google Scholar
• Ohnuma T., Greenspan E. M., Holland J. F. Initial clinical study with vindesine: tolerance to weekly iv bolus and 24-hour infusion. Cancer Treat. Rep. 1980; 64: 25–30
   PubMedGoogle Scholar
• Henderson E. S., Hoelzer D., Freeman A. The treatment of acute lymphoblastic leukemia. Leukemia, E. S. Henderson, T. A. Lister. W. B. Saunders, Philadelphia 1990
   Google Scholar
• Sklaroff R. B., Arlin J., Young C. W. Phase II trial of Vindesine in patients with acute leukemia. Cancer Treat. Rep. 1979; 63: 2063–2065
   PubMedGoogle Scholar
• Gralla R. J., Tan C. T., Young C. W. Vindesine. A review of phase II trials. Cancer Chemother. Pharmacol. 1979; 2: 271–274
   PubMed Web of Science ®Google Scholar
• Vats T. S., Mehta P., Trueworthy R. C., Smith S. D., Klopovich P. Vindesine and prednisone for remission induction in children with acute lymphocytic leukemia. Cancer 1981; 47: 2789–2792
   PubMed Web of Science ®Google Scholar
• Anderson J., Krivit W., Chilcote R., Pyesmany A., Chard R., Hammond D. Comparison of the therapeutic response of patients with childhood acute lymphoblastic leukemia in relapse to vindesine versus vincristine in combination with prednisone and L-asparaginase: a phase III trial. Cancer Treat. Rep. 1981; 65: 1015–1019
   PubMedGoogle Scholar
• Vats T., Buchanan G., Mehta P., Ragab A., Hvizdale E., Nitschke R., Link M., Beardsley G. P., Maybee D., Krischer J. A study of toxicity and comparative therapeutic effkacy of vindesine-prednisone vs. vincristine-pred-nisone in children with acute lymphoblastic leukemia in relapse: A Pediatric Oncology Group study. Invest. New 1992; 10: 231–234, Drugs
   PubMed Web of Science ®Google Scholar
• Garay G., Milone J., Dibar E., Pavlovsky S., Kvicala R., Muriel F. S., Varela D. M., Eppinger-Helft M. Vindesine, prednisone and daunomycin in acute lymphoblastic leukemia in relapse. Cancer Chemother. Pharmacol. 1983; 10: 224–226
   PubMed Web of Science ®Google Scholar
• Freund M., Diedrich H., Ganser A., Gramatzki M., Heil G., Heyll Z., Henke M., Hiddemann W., Haas R., Kuse R., Koch P., Link H., Maschmeyer G., Planker M., Queiber W., Schadeck-Gressel C., Schmitz N., Von Vershuer U., Wilhelm S., Thiel E., Hoelzer D. Treatment of relapsed or refractory adult acute lymphocytic leukemia. Cancer 1992; 69: 709–716
   PubMed Web of Science ®Google Scholar
• Martino R., Brunet S., Sureda A., Mateu R., Altes A., Domingo-Albos A. Treatment of refractory and relapsed adult acute leukemia using a uniform chemotherapy protocol. Leuk. Lymphoma 1993; 11: 393–398
   PubMed Web of Science ®Google Scholar
• Krivit W., Anderson J., Chilcote R., Pyesmany A., Chard R., Hammond D. A study of the cross resistance of vincristine and vindesine in reinduction therapy for acute lymphocytic leukemia in relapse. A report for Children's Cancer Study Group. Am. J. Pediatr. Hematol. Oncol. 1980; 2: 217–231
   PubMedGoogle Scholar
• Saito T., Hikita M., Kohno K., Tanimura H., Miyahara M., Kobayashi M. Enhanced expression of the mul-tidrug resistance gene in vindesine-resistant human esophageal cancer cells. Oncology 1994; 51: 440–445
   PubMed Web of Science ®Google Scholar
• Rivera-Fillat M. P., Pallares-Rujillo J., Domenech C., Grau-Oliete M. R. Comparative uptake, retention and action of vincristine, vinblastine and vindesine on murine leukaemic lymphoblasts sensitive and resistant to vincristine. Br. J. Pharmacol. 1988; 93: 902–908
   PubMed Web of Science ®Google Scholar
• Wilkoff L. J., Dulmadge E. A. Cross-resistance of cultured murine leukemia vincristine-resistant P388 cells to vinblastine, vindesine and bis (N-ethylidene vindesine) disul-fide, disulfate. J. Natl. Cancer Inst. 1982; 68: 1023–1026
   PubMed Web of Science ®Google Scholar
• Maral R., Bourut C., Chenu E., Mathe G. Experimental in vivo cross-resistance of vinca alkaloid drugs. Cancer Chemother. Pharmacol. 1981; 5: 197–199
   PubMed Web of Science ®Google Scholar
• Zhou X. J., Rahmani R. Preclinical and clinical pharmacology of vinca alkaloids. Drugs 1992; 44: 1–16
   PubMedGoogle Scholar
• Rahmani R., Zhou X. J., Cano J. P. Vinca alkaloids: cellular pharmacology and clinical pharmacokinetics. Cancer Surv. 1993; 17: 269–281
   PubMedGoogle Scholar
• Scbaison G., Sommelet D., Bancillon A., Perel Y., Leblanc T., Bergeron C., Lejars O., Baruchel A., Lepage E., Leverger G. Treatment of acute lymphoblastic leukemia French protocol Fralle 83–87. Leukemia 1992; 6: 148–152
   PubMed Web of Science ®Google Scholar
• Koizumi S., Fujimoto T., Takeda T., Yatabe M., Usumi J., Mimajy J., Ninomiya T., Yanai M. Comparison of intermittent or continuous methotrexate plus 6-mercaptopurine in regimens for standard-risk acute lymphoblastic leukemia in childhood (JCCLSG-S811). The Japanese Children's Cancer and Leukemia Study Group. Cancer 1988; 61: 1292–1300
   PubMed Web of Science ®Google Scholar
• Reiter A., Schrappe M., Ludwig W. D., Hiddemann W., Sauter S., Henze G., Lampert F., Havers W., Niethammer D., Odenwald E., Ritter J., Mann G., Welte K., Gadner H., Riehm H. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994; 84: 3122–3133
   PubMed Web of Science ®Google Scholar
• Reiter A., Schrappe M., Yakisan E., Sauter S., Ebell W., Zimmermann M., Hartmann W., Kremens B., Kuhn N., Claviez A., Sauerbrey A., Schmidt P., MÜ-Weihrich S., Lieber T., Riehm H. Therapiestudie NHL-BFM 90 zur Behandlung maligner Non-Hodgkin-Lymphome bei Kindern und Jugendlichen. Teil 3: Eine Zwischenanalyse der Therapiegruppe B-NHLIB-ALL. Klin. Padiatr. 1994; 206: 242–252
   PubMed Web of Science ®Google Scholar
• Henze G., Fengler R., Hartmann R., Kornhuber B., Janka-Schaub G., Niethammer D., Riehm H. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. Blood 1991; 78: 1166–1172
   PubMed Web of Science ®Google Scholar
• Lemoine F., Najman A., Laporte J. P., Gorin N. C., Duhamel G. Vindesine-prednisone in the treatment of blast crisis of chronic myeloid leukemia. Cancer Treat. Rep. 1985; 69: 203–204
   PubMedGoogle Scholar
• Uzuka Y., Saito Y. Treatment of chronic myel-ogenous leukemia in blastic crisis with chemotherapy incorporating vindesine-prednisolone. Cancer Treat. Rep. 1985; 69: 1297–1299
   PubMedGoogle Scholar
• Bayssas M., Gouveia J., Ribaud P., Musset M., De Vassal F., Pico J. L., De Luca L., Misset J. L., Machover D., Belpomme D., Schwarzenberg L., Jasmin C., Hayat M., Mathe G. Phase II trial with vindesine for regression induction in patients with leukemia and hematosarcomas. Cancer Chemother. Pharmacol. 1979; 2: 247–255
   PubMed Web of Science ®Google Scholar
• Nitsche D., Tschurtschenthaler G., Stoger M., Michlmayr G. Blastenkrise der chronischen myelois-chen Leukämie. Ergebnisse mit Vindesin Prednisolon. Dtsch. Med. Wochenschr. 1985; 110: 1936–1939
   PubMed Web of Science ®Google Scholar
• Hulhoven R., Michaux J. L., Comu G., Ferrant A., Symann M., Bosly A., Delannoy A., Dutrieux-Fauchet M. C., Sokal G. Vindesine and prednisone in the treatment of relapsed lymphomalignancies, blastic crisis of chronic myelo-cytic leukemia and acute myelomonocytic leukemia. Proceedings of the International Vinca Alkaloid Symposium—. Vindesine 1980; 6: 143–150, b).
   Google Scholar
• Jehn U., Mezger J. Treatment of chronic myeloid leukemia blast crisis with vindesine and prednisone. Cancer Treat Rep. 1985; 69: 445–448
   PubMedGoogle Scholar
• Engelhardt R., Boss K., Weber M., MÖBius W., LÖHr G. W. Phase II trial with vindesine in patients with hema-tological malignancies mainly in blastic crisis of chronic myelogenous leukemia. Proceedings of the International Vinca Alkaloid Symposium—. Vindesine 1980; 6: 134
   Google Scholar
• Kaspers G. J., Kardos G., Pieters R., Van Zantwijk C. H., Klumper E., Hahlen K., De Waal F. C., Van Wering E. R., Veermann A. J. Different cellular drug resistance profiles in childhood lymphoblastic and non-lymphoblastic leukemia: a preliminary report. Leukemia 1994; 8: 1224–1229
   PubMed Web of Science ®Google Scholar
• Schlaifer D., Cooper M. R., Attal M., Sartor A. O., Trepel J. B., Laurent G., Myers C. E. Myeloperoxidase: an enzyme involved in intrinsic vincristine resistance in human myeloblastic leukemia. Blood 1993; 81: 482–489
   PubMed Web of Science ®Google Scholar
• Chello P. L., Sirotnak F. M. Increased schedule dependent synergism of vindesine versus vincristine in combination with methotrexate against L1210 leukemia. Cancer Treat. Rep. 1981; 65: 1049–1053
   PubMedGoogle Scholar
• Otter G. M., Sirotnak F. M. Effective combination therapy of metastatic murine solid tumors with edatrexate and the vinca alkaloids, vinblastine, navelbine and vindesine. Cancer Chemother. Pharmacol. 1994; 33: 286–290
   PubMed Web of Science ®Google Scholar
• Vorobiof D. A., Bezwoda W. R. A randomised trial of vindesine plus interferon-alpha2b or vindesine alone in the treatment of advanced malignant melanoma. Eur. J. Cancer 1994; 30: 797–800
   Web of Science ®Google Scholar
• Zhou X. J., Zhou-Pan X. R., Gauthier T., Placidi M., Maurel P., Rahmani R. Human liver microsoma cytochrome P450 3A isozymes mediated vindesine biotrans-formation. Metabolic drug interactions. Biochem. Pharmacol. 1993; 45: 853–861
   PubMed Web of Science ®Google Scholar
• Kiue A., Sano T., Naito A., Inada H., Suzuki K., Okumura M., Kikuchi J., Sato S., Takano H., Kohno K. Reversal by two dihydropyridine compounds of resistance to multiple cancer agents in mouse P388 leukemia in vivo and in vitro. Jpn. J. Cancer Res. 1990; 81: 1057–1064
   PubMedGoogle Scholar
• Young A. R., Jurd J., Vincent P. C. Vindesine in the treatment of refractory haematological malignant disease. Med. J. Aust. 1985; 142: 189–190
   PubMed Web of Science ®Google Scholar